



#3

RECEIVED

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 15 2002

Re Application of: Gennady MERKULOV et al. Art Unit: 1652

TECH CENTER 1600/2900

Serial No.: 10/014,501

Examiner: C. Fronda

Filed: December 14, 2001

Atty. Docket: CL001177 DIV2

For: ISOLATED HUMAN METALLOPROTEASE PROTEINS,  
NUCLEIC ACID MOLECULES ENCODING HUMAN  
PROTEASE PROTEINS, AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under  
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

CELERA GENOMICS

Date: October 11, 2002

By:   
Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Celera Genomics Corporation  
45 West Gude Drive, C2-4#20  
Rockville, MD 20850  
Tel: 240-453-3067  
Fax: 240-453-3084

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 2

**Complete if Known**

<b>Application Number</b>	10/014,501
<b>Filing Date</b>	December 14, 2001
<b>First Named Inventor</b>	Gennday MERKULOV et al.
<b>Art Unit</b>	1652
<b>Examiner Name</b>	C Fronda
<b>Attorney Docket Number</b>	CL001177 DIV2

**U.S. PATENT DOCUMENTS**

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY			
		International Search Report	09-19-2002	ISA		
		WO 97/31931 A	09-04-1997	Tindal Michael Howard	entire document	
		WO 01/62905 A	08-30-2001	FANSLOW, William C		

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	10/014,501
<b>Filing Date</b>	December 14, 2001
<b>First Named Inventor</b>	Gennday MERKULOV et al.
<b>Group Art Unit</b>	1652
<b>Examiner Name</b>	C Fronda
<b>Attorney Docket Number</b>	CL001177 DIV2

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T <sup>2</sup>
		<p>DATABASE EMBLE 'Online! Accession No. U41767; KRATZSCHMAR, J. et al., March 23, 1996</p> <p>KRATZSCHMAR, J et al.: "Metargidin, a membrane-anchored metalloprotease-disintegrin protein with an RGD integrin binding sequence." Journal of Biological Chemistry, vol. 271 no. 9, pages 4593-4596: March 1, 1996</p> <p>WU, E et al. "Expression of members of the novel membrane linked metalloproteinase family adam in cells derived from a range of haematological malignancies." Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, FL, US; vol. 235 no. 2, pages 437-442: June 18, 1997</p> <p>POINDEXTER, K et al. "The identification of seven metalloproteinase-disintegrin (ADAM) genes from genomic libraries" Gene, Elsevier Biomedical Press., Amsterdam, NL, vol. 237 no. 1, pages 61-70: September 3, 1999</p> <p>STONE, Ann L et al. "Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review)." Journal of Protein Chemistry, vol. 18 no. 4, pages 447-465: May 1999</p> <p>MOSS, Marcia L et al. "TACE and other ADAM proteases as targets for drug discovery." Drug Discovery Today, vol. 6 no. 8, pages 417-426: April 15, 2001</p>	

RECEIVED  
OCT 15 2002  
TECH CENTER 1600/2500

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.